Zoetis Inc. (NYSE:ZTS) Stake Increased by Investors Asset Management of Georgia Inc. GA ADV

Investors Asset Management of Georgia Inc. GA ADV lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,120 shares of the company’s stock after buying an additional 101 shares during the period. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Zoetis were worth $345,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. AMF Tjanstepension AB grew its stake in Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after acquiring an additional 20,001 shares in the last quarter. Howard Capital Management Group LLC boosted its holdings in shares of Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the period. Allspring Global Investments Holdings LLC grew its position in Zoetis by 8.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock valued at $10,882,000 after purchasing an additional 4,107 shares in the last quarter. Raleigh Capital Management Inc. increased its stake in Zoetis by 128.5% in the 3rd quarter. Raleigh Capital Management Inc. now owns 361 shares of the company’s stock valued at $71,000 after buying an additional 203 shares during the period. Finally, Commerzbank Aktiengesellschaft FI increased its stake in Zoetis by 39.6% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 2,590 shares of the company’s stock valued at $507,000 after buying an additional 735 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $157.38 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm has a fifty day simple moving average of $166.86 and a 200-day simple moving average of $178.14. The stock has a market capitalization of $70.47 billion, a price-to-earnings ratio of 28.77, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.27%. Zoetis’s payout ratio is 36.56%.

Analysts Set New Price Targets

Several equities analysts have recently commented on ZTS shares. Stifel Nicolaus lowered their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Piper Sandler cut their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average price target of $214.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.